| abstract |
The invention provides an improved composition of the bacterial vaccine Mycoplasma hyopneumoniae, which preferably provides immunity from infections after a single administration. The composition consists of an inactivated bacterium Mycoplasma hyopneumoniae and a mixture of excipients, which in combination, provide immunity to Mycoplasma hyopneumoniae infections after a single administration and elicit an immune response specific to Mycoplasma hyopneumoniae, including cell-mediated immunity and local (IgA secretion) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol and a metabolic oil mixture, such as one or more unsaturated terpenic hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include preservatives, preferably thimerosol and / or EDTA. |